The pharma major beat analysts’ expectations in the fourth quarter of 2024, despite looming competition for its top heart ...
The American CEO of Swiss drugmaker Novartis on Friday warned that the United States' exit from the World Health Organization ...
Novartis has finally given up on iscalimab after deciding that the anti-CD40 antibody is not worth pursuing in Sjögren’s ...
In a report released today, Eric Le Berrigaud from Stifel Nicolaus maintained a Hold rating on Novartis AG (NOVN – Research Report), with a ...
After parting ways with BeiGene in 2023, Novartis effectively bowed out of the PD-1 race. | The rising class of bisepcifics ...
Swiss pharmaceutical giant Novartis (NVS) on Friday reported forecast-beating quarterly sales as its clutch of heart failure to breast cancer ...
BASEL, Switzerland (AP) — BASEL, Switzerland (AP) — Novartis AG (NVS) on Friday reported fourth-quarter net income of $2.82 billion. On a per-share basis, the Basel, Switzerland-based company said it ...
To direct more attention toward the importance of regular breast cancer screenings, Novartis is taking to one of television’s ...
Novartis said profit will rise this year as new medicines help offset competition from copycats of its best-selling drug.
In addition to the partnership with Steinfeld and Sykes, Novartis is collaborating on awareness efforts and advocacy events ...
Ad hoc announcement pursuant to Art. 53 LR Full year Net sales grew +12% (cc1, +11% USD) with core operating income1 up +22% (cc, +19% USD) Sales growth driven by continued strong performance ...
Novartis, a global leader in breast cancer care, today announced the launch of the "Your Attention, Please" campaign, which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback